Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells

Armbruster, 2008, Limit of blank, limit of detection and limit of quantitation, Clin. Biochem. Rev., 29, S49

Cohen, 2019, B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma, J. Clin. Invest., 129, 2210, 10.1172/JCI126397

Della Starza, 2019, Minimal residual disease (MRD) in non-Hodgkin lymphomas: interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network, Hematol. Oncol., 37, 368, 10.1002/hon.2652

Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat. Med., 24, 563, 10.1038/s41591-018-0010-1

Franke, 2020, Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia, J. Mol. Diagn., 22, 81, 10.1016/j.jmoldx.2019.08.007

Garand, 2013, Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL, Leukemia, 27, 370, 10.1038/leu.2012.234

Hirayama, 2019, The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells, Blood, 133, 1876, 10.1182/blood-2018-11-887067

Klein-Scory, 2018, Significance of liquid biopsy for monitoring and therapy decision of colorectal cancer, Transl. Oncol., 11, 213, 10.1016/j.tranon.2017.12.010

Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388

Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931

Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol. Blood Marrow Transplant., 25, 625, 10.1016/j.bbmt.2018.12.758

Link-Lenczowska, 2018, A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs, Ann. Hematol., 97, 2299, 10.1007/s00277-018-3451-1

Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial, Lancet Oncol., 20, 31, 10.1016/S1470-2045(18)30864-7

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Mika, 2019, Digital droplet PCR-based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation, Int. J. Lab. Hematol., 41, 615, 10.1111/ijlh.13073

Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol. Ther., 17, 1453, 10.1038/mt.2009.83

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447

Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N. Engl. J. Med., 378, 449, 10.1056/NEJMoa1709919

Pott, 2019, MRD detection in B-cell non-hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR, Methods Mol. Biol., 1956, 199, 10.1007/978-1-4939-9151-8_9

Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N. Engl. J. Med., 380, 45, 10.1056/NEJMoa1804980

Committee for Medicinal Products for Human Use22738111LondonAssessment report YESCARTA2018